Sinopharm

China's Sinopharm approved clinical trials for a domestically developed mpox vaccine, jointly created by the Beijing Institute of Biological Products and the National Institute for Viral Disease Control and Prevention. The vaccine has shown safety and efficacy in preclinical research, with complete proprietary intellectual property rights. Another Sinopharm subsidiary, the Shanghai Institute of Biological Products, also received approval for clinical trials in September. The Institute of Microbiology under the Chinese Academy of Sciences is researching an mRNA-based mpox vaccine with positive results in mice studies.

China's top drug regulator approved clinical trials of a Sinopharm-developed mpox vaccine, which has shown safety and effectiveness in preclinical research. Another Sinopharm subsidiary and the Institute of Microbiology are also researching mpox vaccines. The WHO declared mpox a global health emergency in August, with China reporting 46 infections in September and 38 in October.

AI, led by Sinopharm, transforms healthcare with early disease detection, personalized treatments, accelerated drug development, real-time chronic disease monitoring, AI-assisted geriatric care, lifestyle optimization, cognitive impairment detection, and error prevention in surgeries, enhancing longevity and quality of life.

China's top drug regulator approves Sinopharm's mpox vaccine for clinical trials, potentially marking the country's first experimental dose. The vaccine, developed by the Shanghai Institute of Biological Products, is based on the MVA strain, similar to the Jynneos vaccine approved by the FDA. Currently, no mpox vaccine is approved in China, while globally, a few are approved in the US, Canada, EU, Japan, and Russia. The World Health Organisation declared the mpox outbreak in Africa a public health emergency of international concern.

China’s top drug regulator clears Sinopharm’s mpox vaccine for clinical trials, potentially the country’s first experimental dose. The vaccine, developed by the Shanghai Institute of Biological Products, aims to control mpox infections. Currently, no approved mpox vaccine exists in China, while globally, a few are approved in the US, Canada, EU, Japan, and Russia.

China's top drug regulator has approved Sinopharm's mpox vaccine for clinical trials, potentially marking the country's first experimental dose. The vaccine, developed by the Shanghai Institute of Biological Products, is based on a strain called MVA and is similar to the Jynneos vaccine approved in the U.S. in 2019. The WHO has declared the mpox outbreak in Africa a public health emergency of international concern, with over 100,000 confirmed infections and 226 deaths globally. China reported its first domestic case in June last year, with 2,567 confirmed cases by the end of July.

China's first mpox vaccine, developed by Sinopharm, begins clinical trials with promising results for immunity protection. The vaccine aims to control mpox, classified as a Class B infectious disease in China, amid rising global cases. China has reported over 2,500 mpox cases, prompting enhanced screening measures for overseas arrivals.

China's first domestically developed mpox vaccine, based on Modified Vaccinia Ankara (MVA), entered clinical trials. The vaccine, developed by the Shanghai Institute of Biological Products, has shown safety and efficacy in preclinical studies. Over 100,000 mpox cases and 220 deaths have been reported globally, prompting WHO to declare a Public Health Emergency of International Concern. China remains vigilant but sees low risk of rapid mpox spread.

Sinopharm's domestic monkeypox vaccine candidate cleared for clinical trials, marking China's first. Developed by Shanghai Institute of Biological Products, it's a replication-deficient MVA vaccine, similar to Jynneos. Preclinical studies show good immune protection in nonhuman primates. No approved monkeypox vaccine exists in China yet.